| Market Capitalization (Millions $) |
146 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
8 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-51 |
| Cash Flow (TTM) (Millions $) |
38 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
The company is a biopharmaceutical firm engaged in the development and commercialization of product candidates, including tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB). Its activities include clinical development, regulatory approval processes, and plans to establish commercial operations in the United States and international markets.
Company Address: 611 Gateway Boulevard South San Francisco 94080 CA
Company Phone Number: 343-5986 Stock Exchange / Ticker: NASDAQ SPRB
|
12.9% 